Clinical trials of glycoprotein IIb/IIIa inhibitors.

Abstract

Glycoprotein (GP) IIb/IIIa inhibitors were developed to block platelet aggregation and potentially to abolish thrombus formation. Clinical trials have demonstrated that GP IIb/IIIa inhibitors are more potent antithrombotic agents than aspirin and heparin alone. GP IIb/IIIa inhibitors reduce short- and long-term complications of percutaneous revascularization. These agents also are effective as adjuncts to various treatment strategies for the management of patients with unstable angina (UA) or non-Q-wave myocardial infarction (NQMI). Furthermore, recent clinical trials with a small number of patients suggest that GP IIb/IIIa inhibitors in combination with low-dose fibrinolytics are safe and effective for the treatment of ST segment elevation myocardial infarction. The clinical trials of GP IIb/IIIa inhibitors summarized here examined different patient populations managed under different strategies. Moreover, these agents have different indications for clinical use and varying safety profiles.

• Authors: J D Talley
• Journal: Journal of interventional cardiology (J Interv Cardiol) Vol. 14 Issue 2 Pg. 129-42 (Apr 2001) ISSN: 0896-4327 [Print] United States
• PMID: 12053294 (Publication Type: Journal Article, Review)

Chemical References

• Platelet Glycoprotein GPIIb-IIIa Complex

Topics

• Angina, Unstable (therapy)
• Angioplasty, Balloon, Coronary
• Humans
• Myocardial Infarction (therapy)
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
• Randomized Controlled Trials as Topic